NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
1-Year Return
12.08%
This Quarter Return
-6.17%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.65B
AUM Growth
-$362M
(-18%)
Cap. Flow
-$194M
Cap. Flow
% of AUM
-11.72%
Top 10 Holdings %
Top 10 Hldgs %
71.92%
Holding
40
New
3
Increased
6
Reduced
6
Closed
6
Top Buys
| 1 |
Recursion Pharmaceuticals
RXRX
|
$68.4M |
| 2 |
ASML
ASML
|
$22.5M |
| 3 |
CBLL
CeriBell, Inc. Common Stock
CBLL
|
$8.51M |
| 4 |
Mersana Therapeutics
MRSN
|
$6.08M |
| 5 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$3.69M |
Top Sells
| 1 |
Corcept Therapeutics
CORT
|
$112M |
| 2 |
Cable One
CABO
|
$41.4M |
| 3 |
Brookfield
BN
|
$39.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$32.6M |
| 5 |
Brookfield Asset Management
BAM
|
$29.7M |
Sector Composition
| 1 | Healthcare | 55.4% |
| 2 | Technology | 13.01% |
| 3 | Financials | 9.73% |
| 4 | Consumer Discretionary | 2.32% |
| 5 | Industrials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBLL
26
CeriBell, Inc. Common Stock
CBLL
$433M
| $8.51M | 0.52% |
+328,809
| New | +$8.51M |
|
27
4D Molecular Therapeutics
FDMT
$340M
| $8.36M | 0.51% |
1,500,000
| – | – |
|
28
Lexeo Therapeutics
LXEO
$271M
| $7.39M | 0.45% |
1,122,581
| – | – |
|
29
Kyverna Therapeutics
KYTX
$170M
| $6.92M | 0.42% |
1,850,000
| – | – |
|
|
30
Mersana Therapeutics
MRSN
$34M
| $6.08M | 0.37% |
+170,000
| New | +$6.08M |
|
31
AbCellera Biologics
ABCL
$1.26B
| $3.3M | 0.2% |
1,126,915
| – | – |
|
32
IO Biotech
IOBT
$128M
| $3.09M | 0.19% |
3,354,449
| – | – |
|
33
Marqeta
MQ
$2.76B
| $1.67M | 0.1% |
441,558
| – | – |
|
34
Galecto
GLTO
$3.99M
| $465K | 0.03% |
99,913
| – | – |
|
|
35
Alnylam Pharmaceuticals
ALNY
$59.2B
| – | – |
-118,383
| Closed | -$32.6M |
|
|
36
Brookfield Asset Management
BAM
$94B
| – | – |
-627,207
| Closed | -$29.7M |
|
|
37
Cable One
CABO
$922M
| – | – |
-118,403
| Closed | -$41.4M |
|
|
38
Corcept Therapeutics
CORT
$7.31B
| – | – |
-2,411,362
| Closed | -$112M |
|
39
Spero Therapeutics
SPRO
$121M
| – | – |
-468,902
| Closed | -$628K |
|
40
Metagenomi
MGX
$71.7M
| – | – |
-1,800,000
| Closed | -$3.91M |
|